PetMed Express, Inc. (NASDAQ:PETS) released its earnings results on Monday, July 24th. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.07, MarketWatch Earnings reports. The firm had revenue of $79.66 million during the quarter, compared to analyst estimates of $77.32 million. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The business’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 EPS.
Shares of PetMed Express (NASDAQ PETS) opened at 47.76 on Friday. The stock’s 50 day moving average is $43.59 and its 200 day moving average is $30.19. PetMed Express has a 1-year low of $18.90 and a 1-year high of $50.90. The company has a market capitalization of $969.15 million, a PE ratio of 36.74 and a beta of 0.99.
The business also recently declared a quarterly dividend, which will be paid on Friday, August 18th. Stockholders of record on Monday, August 7th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.80 annualized dividend and a dividend yield of 1.68%. PetMed Express’s dividend payout ratio (DPR) is currently 61.54%.
In related news, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the transaction, the director now directly owns 67,333 shares in the company, valued at approximately $3,244,103.94. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert C. Schweitzer sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total value of $122,950.00. Following the transaction, the director now owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,333 shares of company stock valued at $1,126,330. Corporate insiders own 4.00% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in shares of PetMed Express during the second quarter valued at about $18,691,000. Oaktop Capital Management II L.P. bought a new stake in PetMed Express during the second quarter valued at $15,171,000. Vanguard Group Inc. raised its stake in PetMed Express by 21.0% in the second quarter. Vanguard Group Inc. now owns 1,300,725 shares of the company’s stock valued at $52,810,000 after buying an additional 225,474 shares during the last quarter. Renaissance Technologies LLC raised its stake in PetMed Express by 11.8% in the first quarter. Renaissance Technologies LLC now owns 1,786,315 shares of the company’s stock valued at $35,976,000 after buying an additional 188,615 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in PetMed Express by 24.0% in the first quarter. Dimensional Fund Advisors LP now owns 794,669 shares of the company’s stock valued at $16,005,000 after buying an additional 153,709 shares during the last quarter. 78.36% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://transcriptdaily.com/2017/08/13/petmed-express-inc-nasdaqpets-posts-quarterly-earnings-results-beats-estimates-by-0-07-eps-updated-updated.html.
PETS has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of PetMed Express from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research report on Wednesday, May 10th. Craig Hallum cut shares of PetMed Express from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Northcoast Research raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Monday, July 24th. Finally, Noble Financial reissued a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $35.00.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.